Pre-made Sutimlimab benchmark antibody ( Whole mAb, anti-C1S therapeutic antibody, Anti-EDSPD2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-537
Pre-Made Sutimlimab biosimilar, Whole mAb, Anti-C1S Antibody: Anti-EDSPD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Sutimlimab (INN; development code BIVV009) is a monoclonal antibody that is being investigated for cold agglutinin disease.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Sutimlimab biosimilar, Whole mAb, Anti-C1S Antibody: Anti-EDSPD2 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Preregistration|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Bioverativ;True North Therapeutics|
|Conditions Active||Autoimmune haemolytic anaemia;Idiopathic thrombocytopenic purpura|
|Conditions Discontinued||Bullous pemphigoid;Renal transplant rejection|